Parkinson’s drug looking good
Although drugs to treat Parkinson’s disease have been few and far-between, the approval of Mirapex could help to change all that, says Paul Maestrone, MD, director of scientific and medical affairs at the Staten Island, NY-based American Parkinson’s Disease Association. SmithKline Beecham’s dopamine-agonist, ropinirole, has performed well in recent clinical trials and could be on its way to winning FDA clearance. (See DSM, July 1997, pp. 87-88.) And two other drugs, from Hoffman-LaRoche of Nutley, NJ, and Novartis, are currently under consideration at the FDA, Maestrone notes.
[For more information about Mirapex, contact Pharmacia & Upjohn at (800) 821-7000.]
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content